Related Experiment Video
Updated: Jul 15, 2025

07:39
Mouse In Vivo Placental Targeted CRISPR Manipulation
Published on: April 14, 2023
2.7K
Induction of labor with prostaglandins for pregnancies with small for gestational age neonates
Maranda V Sullivan1, Amanda J Young2, Priyanka Pawar2
1Department of Maternal-Fetal Medicine, Geisigner Medical Center, Danville, PA 17822.
American Journal of Obstetrics & Gynecology MFM
|September 30, 2023
Abstract
No abstract available in PubMed .
Related Concept Videos
Local Anesthetics: Clinical Application as Epidural Anesthesia
452
Epidural anesthetics are administered in the fat-filled epidural space, the outermost part of the spinal canal. This technique is commonly employed for pain management and anesthesia during lower abdomen and pelvis surgeries or labor and delivery.
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
452
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
478
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
478
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
203
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
203

